Patents by Inventor Rolf A. Brekken

Rolf A. Brekken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody kits for selectively inhibiting VEGF
    Patent number: 6887468
    Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: May 3, 2005
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Rolf A. Brekken
  • Methods for imaging tumor vasculature using conjugates that bind to aminophospholipids
    Publication number: 20050089523
    Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.
    Type: Application
    Filed: November 12, 2004
    Publication date: April 28, 2005
    Inventors: Philip Thorpe, Sophia Ran, Rolf Brekken
  • Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
    Patent number: 6818213
    Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: November 16, 2004
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
  • Combined cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
    Patent number: 6783760
    Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: August 31, 2004
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
  • Antibody conjugate methods for selectively inhibiting VEGF
    Patent number: 6703020
    Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: March 9, 2004
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Rolf A. Brekken
  • Antibody conjugate formulations for selectively inhibiting VEGF
    Patent number: 6676941
    Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: January 13, 2004
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Rolf A. Brekken
  • Antibody methods for selectively inhibiting VEGF
    Publication number: 20030175276
    Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
    Type: Application
    Filed: February 24, 2003
    Publication date: September 18, 2003
    Applicant: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Rolf A. Brekken
  • Antibody methods for selectively inhibiting VEGF
    Patent number: 6524583
    Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: February 25, 2003
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Rolf A. Brekken
  • Antibody conjugate formulations for selectively inhibiting VEGF
    Publication number: 20020119153
    Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
    Type: Application
    Filed: November 30, 2001
    Publication date: August 29, 2002
    Applicant: Board of Regents,The University of Texas System
    Inventors: Philip E. Thorpe, Rolf A. Brekken
  • Antibody conjugate kits for selectively inhibiting VEGF
    Patent number: 6416758
    Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: July 9, 2002
    Assignee: Board of Regents, The University of Texax System
    Inventors: Philip E. Thorpe, Rolf A. Brekken
  • Antibody compositions for selectively inhibiting VEGF
    Patent number: 6342219
    Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: January 29, 2002
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Rolf A. Brekken
  • Antibody conjugate compositions for selectively inhibiting VEGF
    Patent number: 6342221
    Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: January 29, 2002
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Rolf A. Brekken